Anti-thymocyte globulin induction with delayed introduction of tacrolimus preserves renal function in pediatric liver transplant recipients
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Mar 2023 · 1 min read
In brief
In brief
This study demonstrates that ATG induction with delayed tacrolimus introduction significantly preserves renal function in pediatric liver transplant recipients at 6 and 12 months post-transplant, without increasing rejection, infection, or mortality rates compared to standard immunosuppression.
Written by the GCMD Library team from the article.
Statements in this article
Tacrolimus-mediated renal disease occurs in up to 70% of pediatric liver transplant recipients.
Children under age 18 years who received isolated liver transplant with a GFR less than 70 received renal-sparing protocol consisting of anti-thymocyte globulin with methylprednisolone, delayed tacrolimus administration, lower initial tacrolimus trough goals, and mycophenolate mofetil.
The renal-sparing group had significantly lower mean tacrolimus trough levels at 30 days post-transplant compared to standard immunosuppression (10.3 vs. 13.2, p = .001).
Renal function was significantly preserved at 6 months post-transplant in the renal-sparing versus standard immunosuppression group as measured by mean change in serum creatinine (-0.26 vs. 0.21, p = .004).
Renal function was significantly preserved at 12 months post-transplant in the renal-sparing versus standard immunosuppression group as measured by mean change in serum creatinine (-0.33 vs. 0.11, p = .003).
Acute cellular rejection, sepsis, viremia, graft loss and mortality occurred at similar rates in both renal-sparing and standard immunosuppression groups.